The effect of serum levetiracetam concentrations on therapeutic response and IL1-beta concentration in patients with epilepsy

Gulcebi, Medine I.; Kendirli, Tansel; Turgan, Zehra Asik; Patsalos, Philip N.; Onat, Filiz

doi:10.1016/j.eplepsyres.2018.09.015

Cited by 6 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Still, addition of other ASMs was not inferior to increasing dose of LEV and adverse events were also tolerable. As for increasing the LEV dose, high blood levels of LEV might increase the incidence of adverse events [ 27 , 33 ]. However, this study showed that adverse event rates in patients receiving increasing dose of LEV were low (1/43, 2.3%), suggesting that increasing dose of LEV remains an important option for the treatment of refractory epilepsy.…”

Section: Discussionmentioning

confidence: 99%

Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy

Hattori,

Arakawa,

Mineharu

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Background Epilepsy is a major symptom in patients with glioma. Levetiracetam (LEV) is recognized as a first-line treatment for glioma-related epilepsy. Increasing the LEV dose is allowed into patients with seizure occurrence against its initial dose. However, the therapeutic efficacy of increasing the LEV dose in response to seizure occurrence remains unclear. Methods We retrospectively analyzed 236 glioma patients who were treated with antiseizure medications (ASMs) internally at our institute between September 2010 and December 2017. Of these, the analysis focused on 156 patients treated with LEV who had a clear history of administration. Results Seizure occurrences were observed in 21 of 75 patients (26.7%) who received LEV as first-line therapy and in 33 of 81 patients (40.7%) who received LEV as non-first-line treatment. The seizure control rate for seizure occurrence with LEV as first-line treatment was significantly higher in patients treated with addition of other ASMs (72.7%) than in those treated with increasing dose of LEV (20.0%) (p = 0.016). The seizure control rate for seizure occurrence with LEV as non-first-line treatment did not differ significantly between patients with addition of other ASMs (58.3%) and those treated with increasing dose of LEV (47.6%) (p = 0.554). Conclusions Adding other ASMs was more effective than increasing the LEV dose for seizure control in patients treated with LEV as first-line treatment, but they demonstrated comparable efficacy in patients treated with LEV as non-first-line treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy

Hattori,

Arakawa,

Mineharu

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…In this regard, LEV has been shown to be effective against Alzheimer's pathology that is characterized by the accumulation of the beta-amyloid in the neurons ( Inaba et al, 2019 ). This unique drug also possesses anti-inflammatory effects ( Gulcebi et al, 2018 ). Giemsa-stained cells displayed the neurons, glial cells, and astrocytes.…”

Section: Discussionmentioning

confidence: 99%

In Silico and In Vivo: Evaluating the Therapeutic Potential of Kaempferol, Quercetin, and Catechin to Treat Chronic Epilepsy in a Rat Model

Ahmed

Khan

Zaidi³

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Recently, alternative therapies are gaining popularity in the treatment of epilepsy. The present study aimed to find out the antiepileptic potential of quercetin, catechin, and kaempferol. In vivo and in silico experiments were conducted to investigate their therapeutic potential. 25 mg/kg/day of pentylenetetrazole was administered for 4 weeks after epilepsy was induced in the rats; this was followed by the behavioral studies and histological analysis of rat brain slices. Binding affinities of kaempferol, quercetin, and catechin were assessed by performing in silico studies. Kaempferol, quercetin, and catechin were found to have the highest binding affinity with the synaptic vesicle 2A (SV2A) protein, comparable to standard levetiracetam (LEV). The mRNA levels of SV2A, as well as the expression of TNF, IL 6, IL 1 beta, NFkB, IL 1Ra, IL 4, and IL 10, were investigated using qPCR. Our results indicate for the first time that SV2A is also a transporter of understudied phytoflavonoids, due to which a significant improvement was observed in epileptic parameters. The mRNA levels of SV2A were found to be significantly elevated in the PF-treated rats when compared with those of the control rats with epilepsy. Additionally, downregulation of the pro-inflammatory cytokines and upregulation of the anti-inflammatory cytokines were also noted in the PF-treated groups. It is concluded that kaempferol, quercetin, and catechin can effectively decrease the epileptic seizures in our chronic epilepsy rat model to a level that is comparable to the antiepileptic effects induced by levetiracetam drug.

show abstract

Effect of valproate and add-on levetiracetam on inflammatory biomarkers in children with epilepsy

Labh

Gupta

Narang

et al. 2021

Epilepsy & Behavior

View full text Add to dashboard Cite

The effect of serum levetiracetam concentrations on therapeutic response and IL1-beta concentration in patients with epilepsy

Cited by 6 publications

References 31 publications

Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy

Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy

In Silico and In Vivo: Evaluating the Therapeutic Potential of Kaempferol, Quercetin, and Catechin to Treat Chronic Epilepsy in a Rat Model

Effect of valproate and add-on levetiracetam on inflammatory biomarkers in children with epilepsy

Contact Info

Product

Resources

About